Cel-Sci Corp (AMEX:CVM) (was HIV) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV)

CVM 5.280

+1.9%

Jan 14 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom Shutters who wrote (2671)	9/2/1999 10:35:00 PM
From: Tom Shutters	Read Replies (1) of 2836

What kind of deal can we expect from Cel-Sci and a suitor company? Here is a similar deal I found today. ..."Hoechst Marion Roussel will pay Vertex $20 million in license fees in connection with prior research. Hoechst Marion Roussel will also pay Vertex up to $62 million for the successful development of HMR 3480/VX-740 in rheumatoid arthritis, the first targeted indication. Hoechst Marion Roussel has retained the rights to develop HMR 3480/VX-740 for additional indications and Vertex will receive similar milestones for each additional indication"... newsalert.com This would imply that any company purchasing a license to Multikine could develop it for throat cancer, HIV treatment, leukemia, prostate cancer, etc. A deal like the one above would give Cel-Sci payments for each of these uses and a long line of income. $268 million+ if we use the numbers from the above deal. The 10-Q shows less than 17 million shares. That's over $15/share and just the tip of the iceberg. Anyone have any other examples?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next